AI in Healthcare
The latest on artificial intelligence transforming medicine
News stories discovered and organized by an automated pipeline. Covering clinical deployments, research breakthroughs, regulation, and industry developments.
AI in Healthcare Is No Longer a Side Topic — It’s the Main Event at Precision Medicine Events
Inside Precision Medicine’s symposium coverage suggests that AI is now central to conversations about precision medicine, not merely an adjunct topic. The field appears to be moving toward a more practical debate about what kinds of AI actually fit personalized care.
AI in Genomics Is Emerging as Drug Discovery’s Next Big Lever
A new commentary argues that AI in genomics may be the next major frontier for drug discovery. The thesis is compelling because genomics can provide the biological context AI needs to move from pattern recognition to more meaningful therapeutic insight. If that convergence matures, it could improve target identification, patient stratification, and precision medicine strategies.
Rare disease AI promises progress, but the evidence gap is still the bottleneck
Open Access Government asks whether AI can live up to its promises for rare diseases, where data scarcity and fragmented care have long constrained diagnosis and treatment. The central challenge is not model ambition, but proof in low-volume, high-variability conditions.
AI and Genomics Are Starting to Rewire Prostate Cancer Care
UroToday explores how AI and genomics are converging to change prostate cancer management, from risk stratification to treatment selection. The shift matters because prostate cancer care is increasingly about matching the right intensity of treatment to the biology of the disease, not just the presence of a tumor.
Mount Sinai Uses AI to Speed Genomic Testing, Pointing to a Faster Diagnostic Future
Healthcare IT News reports that Mount Sinai is using AI to accelerate genomic testing. The effort shows how AI is moving into the laboratory, where shorter turnaround times can directly affect diagnosis and treatment decisions.
NeoGenomics Bets on AI-Driven Genomic–Clinical Data Integration as Precision Oncology Gets More Demanding
NeoGenomics says it will spotlight AI-driven genomic–clinical data integration at AACR 2026, highlighting a growing push to connect lab data with treatment decision support. The story reflects how oncology AI is expanding beyond imaging into the harder problem of combining molecular and clinical context. If successful, this kind of integration could improve interpretation, but it also raises the bar for data quality, interoperability, and clinical accountability.
AI in biology is moving from analysis to invention
The Conversation argues that AI is beginning to reshape biology itself, not just data analysis around it. The most significant implication is that medicine may increasingly be built on AI-designed hypotheses, molecules, and models of disease rather than on human-generated trial-and-error alone.
Precision Medicine AI Forecasts Point to Growth, but the Real Battle Is Workflow Ownership
New market projections suggest rapid expansion for AI in precision medicine through 2032. But the commercial upside will depend less on headline market size than on which companies control the clinical workflows, data pipelines, and reimbursement logic that turn prediction into routine care.
Trillion Gene Atlas Expands the Data Foundation for the Next Wave of AI Therapeutics
A newly expanded Trillion Gene Atlas is pushing evolutionary-scale biological datasets into the center of AI therapeutics research. The development matters because better foundation data—not just better models—may be the real limiting factor for the next generation of drug discovery systems.
Going Founder Mode on Cancer: How GitLab's CEO Used AI and Genomics to Fight Osteosarcoma
GitLab CEO Sid Sijbrandij applied his engineering mindset to his own osteosarcoma diagnosis, assembling a team that used single-cell sequencing, AI-guided therapy selection, and experimental treatments to achieve remission after standard oncology protocols failed.
Illumina CEO: 2026 Is a Turning Point for Precision Health
Illumina CEO Jacob Thaysen declared 2026 a transformative year for precision health, unveiling the AI-powered Billion Cell Atlas for disease pathway mapping in partnership with AstraZeneca, Eli Lilly, and Merck, alongside full multiomics integration by year-end.
How this works
Discover
An automated pipeline searches the web for significant AI healthcare news across clinical, research, regulatory, and industry domains.
Structure
The pipeline turns source material into concise, readable stories with categories, tags, and context that make the feed easier to scan.
Publish
Stories are deduplicated, stored, and published to this site. The pipeline runs automatically to keep coverage current.